NEW YORK (GenomeWeb News) – Quebec's government will provide C$10 million (US$9.9 million) over four years to launch a new personalized cancer medicine collaboration between private and public partners that will aim to integrate biomarkers into cancer care and reduce treatment costs.

The new Personalized Medicine Partnership for Cancer also will raise C$11.1 million from private-sector partners, and it will be led by the Montreal-based protein biomarker developer Caprion Proteome, according to the partners in the effort.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.